|
Apr 7
|
Promising Penny Stocks To Consider In April 2025
|
|
Mar 14
|
Are Medical Stocks Lagging Aveanna Healthcare (AVAH) This Year?
|
|
Feb 21
|
Here's Why Equillium (EQ) Is a Great 'Buy the Bottom' Stock Now
|
|
Feb 10
|
Equillium (EQ) Upgraded to Buy: Here's What You Should Know
|
|
Feb 10
|
Equillium (EQ) Shows Fast-paced Momentum But Is Still a Bargain Stock
|
|
Jan 2
|
US Penny Stocks To Watch In January 2025
|
|
Oct 7
|
Equillium Announces Abstract Accepted for Poster Presentation at the Society for Immunotherapy of Cancer
|
|
Sep 10
|
Equillium to Present at the Stifel Virtual Inflammation & Immunology Summit
|
|
Aug 28
|
Equillium to Present at the Wells Fargo Healthcare Conference and the H.C. Wainwright 26th Annual Global Investor Conference
|
|
Jun 12
|
Equillium to be included in the Russell Microcap® Index
|
|
May 29
|
Equillium to Present at the Jefferies Global Healthcare Conference
|
|
May 14
|
Equillium Announces Interim Enrollment Achieved in Phase 3 EQUATOR Study of Itolizumab in Acute Graft-Versus-Host Disease
|
|
May 9
|
Equillium, Inc. (EQ) Reports Q1 Loss, Tops Revenue Estimates
|
|
May 9
|
Equillium Reports First Quarter 2024 Financial Results and Provides Recent Clinical Highlights
|
|
May 7
|
Equillium Announces Poster Presentation at the Annual Meeting of The American Association of Immunologists
|
|
May 2
|
We're Keeping An Eye On Equillium's (NASDAQ:EQ) Cash Burn Rate
|
|
Apr 3
|
Equillium Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
|
|
Apr 1
|
5 Stocks That More Than Doubled in Q1 With More Gains Ahead
|
|
Apr 1
|
Equillium Announces Positive Topline Data from the Type B Portion of the Phase 1b EQUALISE Study of Itolizumab in Lupus Nephritis
|
|
Mar 25
|
Equillium, Inc. (EQ) Reports Q4 Loss, Tops Revenue Estimates
|